PAREXEL INTERNATIONAL CLINICAL RESEARCH PRIVATE LIMITED

George Clinical appoints Tony Proctor, C.P.A., as CFO, leveraging his 25+ years of financial leadership experience to drive operational excellence and strategic growth.

Women remain underrepresented in clinical trials, prompting the launch of Lindus Health's women's health-focused CRO. This CRO aims to address historical gaps by considering ethical and social factors, ensuring true informed consent, and developing strategies to overcome social barriers. Despite increased industry attention, diversity in clinical trials continues to suffer, with underrepresented groups like Black patients, elderly, disabled, indigenous, and transgender and nonbinary people lacking adequate representation. Boosting participation among these groups presents a market opportunity for sponsors.

Sponsors and CROs seek optimal balance in oversight to ensure efficient clinical trials, with concerns over trust and the need for 'just right' oversight highlighted at Veeva’s forum. Effective oversight ensures patient protection, data reliability, and compliance with legislation, balancing costs and efficiency.

The non-small cell lung cancer market is driven by increasing NSCLC cases, uptake of immune checkpoint inhibitors, emerging premium therapies, and awareness of mutations. DelveInsight's report covers current treatment practices, emerging drugs, market share, and forecasted market size from 2019 to 2032 in 7MM. Key companies and therapies include EMD Serono, Merck, AstraZeneca, Bristol-Myers Squibb, and therapies like M1774, C-TIL051, and Osimertinib. FDA approvals for Opdivo and Tagrisso in 2024 highlight advancements in treatment.

Kuwait in vivo CRO market generated USD 5.8 million in 2023, expected to reach USD 9.8 million by 2030 with a CAGR of 7.7%. Small molecule was the largest segment in 2023, while Large Molecule is the fastest growing. Kuwait accounted for 0.1% of the global market in 2023, with the U.S. leading globally and South Africa leading in the Middle East & Africa by 2030.

The South Korea in vivo CRO market generated USD 36.1 million in 2023, projected to reach USD 65.9 million by 2030, growing at a CAGR of 9%. Small molecule was the largest segment in 2023, while Large Molecule is expected to grow fastest. South Korea accounted for 0.8% of the global market in 2023, with the U.S. leading globally and Japan leading in Asia Pacific by 2030. India is the fastest-growing regional market in Asia Pacific, projected to reach USD 122.7 million by 2030.

Parexel’s Cell & Gene Therapy Center of Excellence analyzes FDA expedited designations (BTD, RMAT, FT) for advanced therapies, highlighting BTD’s rigorous criteria and fluctuating success rates, RMAT’s lower threshold and higher requests, and FT’s minimal criteria and validation potential, influencing R&D pipeline decisions.

France in vivo CRO market generated USD 230.2 million in 2023, expected to reach USD 399.6 million by 2030 with an 8.2% CAGR. Small molecule led in 2023, while Large Molecule is fastest growing. Factors driving growth include increasing preclinical studies, outsourcing, skilled professionals, and R&D investments.

Decentralized clinical trials, facilitated by tech like remote monitoring and telemedicine, are expanding access to diverse patient populations and accelerating timelines. Companies like Allucent, Curavit, EmVenio, ObvioHealth, PPD, Science 37, and Vivalink are leading in this space, offering solutions that conduct trials outside traditional settings, enhancing patient-centricity and data quality.

Clinical trial leaders innovate to accelerate drug development, enhance patient diversity, and improve health equity, fostering a new generation of pharma innovation.